News

Novartis has been awarded NVA237’s license by Sosei and its co-development partner Vectura in April 2005. Novartis plans to launch NVA237 as a once-daily monotherapy for COPD in

L-asparaginase, a key component in the treatment of acute lymphoblastic leukemia (ALL), is an enzyme that depletes the amino acid asparagine, which certain leukemic cells are dependent upon

CHMP’s decision was supported by the positive results of a Phase 3b open-label, multicenter study, which investigated the safety and efficacy of AVONEX PEN which demonstarted 89% of

The new single-use device allows an aseptic disconnection of Silicone (Pt) tubing in biopharmaceutical manufacturing processes. Sartorius Stedim claims Clipster Aseptic Disconnector is safe, quick, easy to use

The company’s MAA includes 29 countries using a decentralised procedure (DCP). Registration in Russia, Turkey and the CIS countries will follow. Meda CEO Anders Lonner said Acnex is

Initially, Stirling Products will manufacture 300kgs of tableted products and will gradually increase its production with the signing of more contracts which are now in process. Stirling Products’

The patent application covers methods to improve walking in patients with multiple sclerosis (MS) by administering 10mg of sustained release 4-aminopyridine (dalfampridine) twice daily. Acorda is marketing Ampyra

The test, developed through a non-exclusive license agreement under which Schering, a Merck affiliate, licensed certain patent rights claiming Interleukin (IL) 28B genetic markers to Quest Diagnostics. These

CHMP has recommended the approval for Dabigatran Etexilate in the member states of the EU as the prevention of stroke and systemic embolism in adult patients with nonvalvular